Remote management of osteoporosis in the first wave of the COVID-19 pandemic.
COVID-19
Denosumab
Osteoporosis
SARS-CoV-2
Telemedicine
Vitamin D
Journal
Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988
Informations de publication
Date de publication:
02 03 2022
02 03 2022
Historique:
received:
27
10
2021
accepted:
21
01
2022
entrez:
2
3
2022
pubmed:
3
3
2022
medline:
9
3
2022
Statut:
epublish
Résumé
We conducted a survey during the first pandemic wave of coronavirus disease 2019 (COVID-19) on a large group of osteoporotic patients to evaluate the general conditions of osteoporotic patients and the impact of the pandemic on the management of osteoporosis, finding high compliance to treatments and low COVID-19 lethality. During the first pandemic wave of coronavirus disease 2019 (COVID-19), 209,254 cases were diagnosed in Italy; fatalities were 26,892 and were overwhelmingly older patients. The high prevalence of osteoporosis in this age group suggests a potential relationship between SARS-CoV-2 infection and bone metabolism. In a telephone survey conducted from April to May 2020, patients from the Osteoporosis Center, Clinic of Endocrinology and Metabolic Diseases of Umberto I Hospital (Ancona, Italy), were interviewed to evaluate the general clinical conditions of osteoporotic patients, compliance with osteoporosis medications, COVID-19 prevalence, hospitalization rate, COVID-19 mortality, and lethality. Among the 892 patients interviewed, 77.9% were taking osteoporosis treatment and 94.6% vitamin D supplementation as prescribed at the last visit. COVID-19-like symptoms were reported by 5.1%, whereas confirmed cases were 1.2%. A total number of 33 patients had been in hospital and the hospitalization rate of those who had not discontinued vitamin D supplementation was less than 4%. There were eight deaths, two with a concomitant COVID-19 diagnosis. The prevalence of severe osteoporosis was 50% in total COVID-19 patients and 87.5% in deceased COVID-19 patients. The overall COVID-19 mortality was 0.2%; lethality was 20%, lower than the national rate of the same age group. This large group of osteoporotic patients showed high compliance and lower COVID-19 lethality compared to patients of the same age. Novel approaches such as telemedicine can provide critical support for the remote follow-up of patients with chronic diseases also in the setting of routine care.
Identifiants
pubmed: 35235056
doi: 10.1007/s11657-022-01069-x
pii: 10.1007/s11657-022-01069-x
pmc: PMC8889057
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Informations de copyright
© 2022. The Author(s).
Références
Pedersen SF, Ho Y-C (2020) SARS-CoV-2: a storm is raging. J Clin Invest 130:2202–2205. https://doi.org/10.1172/JCI137647
doi: 10.1172/JCI137647
pubmed: 32217834
pmcid: 7190904
WHO (2020) Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . Accessed 23 Oct 2021
Romagnani P, Gnone G, Guzzi F et al (2020) The COVID-19 infection: lessons from the Italian experience. J Public Health Policy 41:238–244. https://doi.org/10.1057/s41271-020-00229-y
doi: 10.1057/s41271-020-00229-y
pubmed: 32472024
pmcid: 7257358
ISS (2020) Report Isituto Superiore di Sanità per COVID-19
Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Rossini M, Adami S, Bertoldo F, et al (2016) Linee guida per la diagnosi, la prevenzione ed il trattamento dell’osteoporosi. Reumatismo 68:1–42
Nuti R, SIE, SIMFER, SIMI, SIOT, SIGG, SIMG, SIOMMMS S (2017) Commissione Intersocietaria per l’Osteoporosi. Linee Guida sulla gestione dell’Osteoporosi e delle Fratture da fragilità
Epidemiology and economic burden of osteoporosis in Italy | IRIS Verona. https://iris.univr.it/handle/11562/626966#.XpGYIsgzaUk . Accessed 11 Apr 2020
Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. https://doi.org/10.1007/s11657-013-0136-1
doi: 10.1007/s11657-013-0136-1
pubmed: 24113838
pmcid: 3880492
Salvio G, Gianfelice C, Firmani F et al (2020) Bone metabolism in SARS-CoV-2 disease: possible osteoimmunology and gender implications. Clin Rev Bone Miner Metab 1–7. https://doi.org/10.1007/s12018-020-09274-3
Mi B, Chen L, Xiong Y, Xue H, Zhou W, Liu G (2020) Characteristics and early prognosis of COVID-19 infection in fracture patients. J Bone Jt Surg Am 1–9. https://doi.org/10.1080/03056244.2018.1546429
Biarnés-Suñé A, Solà-Enríquez B, González Posada MÁ et al (2021) Impacto de la pandemia COVID-19 en la mortalidad del paciente anciano con fractura de cadera. Rev Esp Anestesiol Reanim 68:65–72. https://doi.org/10.1016/j.redar.2020.10.003
doi: 10.1016/j.redar.2020.10.003
Pluskiewicz W, Wilk R, Adamczyk P et al (2021) The incidence of arm, forearm, and hip osteoporotic fractures during early stage of COVID-19 pandemic. Osteoporos Int. https://doi.org/10.1007/s00198-020-05811-4
doi: 10.1007/s00198-020-05811-4
pubmed: 33818635
pmcid: 8510894
Ojeda-Thies C, Cuarental-García J, Ramos-Pascua LR (2021) Decreased volume of hip fractures observed during COVID-19 lockdown. Eur Geriatr Med. https://doi.org/10.1007/s41999-020-00447-3
doi: 10.1007/s41999-020-00447-3
pubmed: 33970467
pmcid: 7867866
Lim MA, Mulyadi Ridia KG, Pranata R (2020) Epidemiological pattern of orthopaedic fracture during the COVID-19 pandemic: a systematic review and meta-analysis. J Clin Orthop Trauma 16:16–23. https://doi.org/10.1016/j.jcot.2020.12.028
doi: 10.1016/j.jcot.2020.12.028
pubmed: 33398227
pmcid: 7773000
Wake DJ, Gibb FW, Kar P et al (2020) Remodelling diabetes services and emerging innovation. Eur J Endocrinol 183:G67–G77. https://doi.org/10.1530/EJE-20-0377
doi: 10.1530/EJE-20-0377
pubmed: 32508313
pmcid: 7938018
Vrachimis A, Iakovou I, Giannoula E, Giovanella L (2020) Endocrinology in the time of COVID-19: management of thyroid nodules and cancer. Eur J Endocrinol 183:G41–G48
doi: 10.1530/EJE-20-0269
pubmed: 32438345
pmcid: 7938009
Boelaert K, Edward Visser W, Taylor PN et al (2020) Endocrinology in the time of COVID-19: management of hyperthyroidism and hypothyroidism. Eur J Endocrinol 183:G33–G39
doi: 10.1530/EJE-20-0445
pubmed: 32438340
pmcid: 7938012
Fleseriu M, Dekkers OM, Karavitaki N (2020) Endocrinology in the time of COVID-19: management of pituitary tumours. Eur J Endocrinol 183:G17–G23
doi: 10.1530/EJE-20-0473
pubmed: 32369770
pmcid: 7938006
Christ-Crain M, Hoorn EJ, Sherlock M et al (2020) Endocrinology in the time of COVID-19: management of diabetes insipidus and hyponatraemia. Eur J Endocrinol 183:G9–G15
doi: 10.1530/EJE-20-0338
pubmed: 32380474
pmcid: 7938013
Gittoes NJ, Criseno S, Appelman-Dijkstra NM et al (2020) Management of calcium metabolic disorders and osteoporosis. Eur J Endocrinol 183:G57–G65
doi: 10.1530/EJE-20-0385
pubmed: 32396134
pmcid: 7938011
Regione Marche (2020) Report COVID-19 Regione Marche. https://www.regione.marche.it/Regione-Utile/Salute/Coronavirus/Report-contagiati-per-Comune
Sinningen K, Tsourdi E, Rauner M et al (2012) Skeletal and extraskeletal actions of denosumab. Endocrine 42:52–62. https://doi.org/10.1007/s12020-012-9696-x
doi: 10.1007/s12020-012-9696-x
pubmed: 22581255
Dubrovsky AM, Lim MJ, Lane NE (2018) Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton. Calcif Tissue Int 102:607–618. https://doi.org/10.1007/s00223-018-0401-9
doi: 10.1007/s00223-018-0401-9
pubmed: 29470611
Ralston SH, Schett G (2018) Osteoimmunology. Calcif Tissue Int 102:501–502. https://doi.org/10.1007/s00223-018-0421-5
doi: 10.1007/s00223-018-0421-5
pubmed: 29654343
De Martinis M, Ginaldi L, Sirufo MM et al (2020) Alarmins in osteoporosis, RAGE, IL-1, and IL-33 pathways: a literature review. Medicina (B Aires) 56:138. https://doi.org/10.3390/medicina56030138
doi: 10.3390/medicina56030138
Georgiev T (2020) Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int 40:825–826. https://doi.org/10.1007/s00296-020-04570-z
doi: 10.1007/s00296-020-04570-z
pubmed: 32232552
pmcid: 7103900
Formenti AM, Pedone E, di Filippo L et al (2020) Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 70:203–205. https://doi.org/10.1007/s12020-020-02500-4
doi: 10.1007/s12020-020-02500-4
pubmed: 32951069
pmcid: 7502215
Blanch-Rubio J, Soldevila-Domenech N, Tio L, et al (2020) Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY) 12:19923–19937. https://doi.org/10.18632/aging.104117
Colotta F, Jansson B, Bonelli F (2017) Modulation of inflammatory and immune responses by vitamin D. J Autoimmun 85:78–97. https://doi.org/10.1016/j.jaut.2017.07.007
doi: 10.1016/j.jaut.2017.07.007
pubmed: 28733125
Dancer RCA, Parekh D, Lax S et al (2015) Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax 70:617–624. https://doi.org/10.1136/thoraxjnl-2014-206680
doi: 10.1136/thoraxjnl-2014-206680
pubmed: 25903964
Altieri B, Muscogiuri G, Barrea L et al (2017) Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. Rev Endocr Metab Disord 18:335–346. https://doi.org/10.1007/s11154-016-9405-9
doi: 10.1007/s11154-016-9405-9
pubmed: 28070798
Giustina A, Bouillon R, Binkley N et al (2020) Controversies in vitamin D: a statement from the third international conference. JBMR Plus 4:1–13. https://doi.org/10.1002/jbm4.10417
doi: 10.1002/jbm4.10417
Vanherwegen AS, Gysemans C, Mathieu C (2017) Regulation of immune function by vitamin D and its use in diseases of immunity. Endocrinol Metab Clin North Am 46:1061–1094. https://doi.org/10.1016/j.ecl.2017.07.010
doi: 10.1016/j.ecl.2017.07.010
pubmed: 29080635
Bilezikian JP, Bikle D, Hewison M et al (2020) Mechanisms in endocrinology: vitamin D and COVID-19. Eur J Endocrinol 183:R133–R147. https://doi.org/10.1530/EJE-20-0665
doi: 10.1530/EJE-20-0665
pubmed: 32755992
pmcid: 9494342
Merzon E, Tworowski D, Gorohovski A et al (2020) Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J 287:3693–3702. https://doi.org/10.1111/febs.15495
doi: 10.1111/febs.15495
pubmed: 32700398
pmcid: 7404739
Hastie CE, Mackay DF, Ho F et al (2020) Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr Clin Res Rev 14:561–565. https://doi.org/10.1016/j.dsx.2020.04.050
doi: 10.1016/j.dsx.2020.04.050
Singh S, Kaur R, Singh RK (2020) Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. Aging Clin Exp Res 32:1609–1612. https://doi.org/10.1007/s40520-020-01619-8
doi: 10.1007/s40520-020-01619-8
pubmed: 32797388
pmcid: 7426200
Katz J, Yue S, Xue W (2021) Increased risk for COVID-19 in patients with vitamin D deficiency. Nutrition 84:111106. https://doi.org/10.1016/j.nut.2020.111106
doi: 10.1016/j.nut.2020.111106
pubmed: 33418230
Baktash V, Hosack T, Patel N, et al (2020) Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J postgradmedj-2020–138712. https://doi.org/10.1136/postgradmedj-2020-138712
Abrishami A, Dalili N, Mohammadi Torbati P et al (2021) Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. Eur J Nutr 60:2249–2257. https://doi.org/10.1007/s00394-020-02411-0
doi: 10.1007/s00394-020-02411-0
pubmed: 33123774
Cutolo M, Paolino S, Smith V (2020) Evidences for a protective role of vitamin D in COVID-19. RMD Open 6:1–7. https://doi.org/10.1136/rmdopen-2020-001454
doi: 10.1136/rmdopen-2020-001454
Farid N, Rola N, Koch EAT, Nakhoul N (2021) Active vitamin D supplementation and COVID-19 infections: review. Irish J Med Sci (1971 -) 2:. https://doi.org/10.1007/s11845-020-02452-8
Giannini S, Passeri G, Tripepi G et al (2021) Effectiveness of in-hospital cholecalciferol use on clinical outcomes in comorbid COVID-19 patients: a hypothesis-generating study. Nutrients 13:219. https://doi.org/10.3390/nu13010219
doi: 10.3390/nu13010219
pubmed: 33466642
pmcid: 7828675